Please assess the completion status of the following clinical trial:

Trial Title: Effects of Vaginal Lactoferrin Administration Prior to Genetic Amniocentesis on Inflammatory Mediators

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* singleton gestation~* maternal age as indication to fetal karyotyping~Exclusion Criteria:~* consumption of drugs interfering with the immune system~* previous miscarriages~* pregnancy at risk for maternal or fetal disease~* lactose intolerance

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- controls (Type: NO_INTERVENTION): The patients will be not treated with vaginal lactoferrin
- Lactoferrin (Type: ACTIVE_COMPARATOR): The patients will be administered with a single dose of 300 mg vaginal lactoferrin 4 hours prior to mid-trimester genetic amniocentesis.

Based on this trial design, predict the completion outcome and termination type (if applicable).